MeSH term
Frequency | Condition_Probility | Cell Line, Transformed | 9 | 0.0 |
DNA/radiation effects | 5 | 19.0 |
*DNA Damage | 44 | 7.0 |
DNA Repair | 25 | 3.0 |
DNA-Binding Proteins | 2 | 2.0 |
Fibroblasts | 6 | 1.0 |
Humans | 327 | 0.0 |
Models, Genetic | 12 | 0.0 |
Phosphorylation | 59 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 9 | 1.0 |
Research Support, Non-U.S. Gov't | 219 | 0.0 |
Male | 82 | 0.0 |
Radiation Tolerance/*physiology | 2 | 14.0 |
Adult | 61 | 0.0 |
Aged | 30 | 0.0 |
Aged, 80 and over | 14 | 0.0 |
DNA Mutational Analysis | 18 | 0.0 |
DNA Primers | 8 | 0.0 |
Female | 99 | 0.0 |
Genetic Predisposition to Disease | 9 | 0.0 |
Leukemia, Lymphocytic, Chronic/*genetics | 3 | 13.0 |
Middle Aged | 43 | 0.0 |
*Mutation | 20 | 0.0 |
Protein-Serine-Threonine Kinases/*genetics | 40 | 13.0 |
Ataxia Telangiectasia/*genetics | 34 | 51.0 |
Cell Cycle Proteins/*metabolism | 5 | 1.0 |
Chromosome Breakage/*genetics | 2 | 3.0 |
Comparative Study | 17 | 0.0 |
Dose-Response Relationship, Radiation | 6 | 1.0 |
*Genes, cdc | 2 | 9.0 |
Histones/metabolism | 8 | 3.0 |
Nuclear Proteins/*metabolism | 5 | 0.0 |
Protein Kinases/metabolism | 4 | 0.0 |
Protein p53/metabolism | 24 | 3.0 |
Protein-Serine-Threonine Kinases/*metabolism | 21 | 3.0 |
Radiation Tolerance/genetics | 6 | 12.0 |
S Phase/*physiology | 2 | 4.0 |
Syndrome | 10 | 0.0 |
Androstadienes/pharmacology | 8 | 3.0 |
Cell Line | 53 | 0.0 |
Cell Survival/radiation effects | 3 | 3.0 |
*DNA-Binding Proteins | 9 | 0.0 |
G1 Phase/physiology/radiation effects | 2 | 100.0 |
Hela Cells | 13 | 0.0 |
Serine/chemistry | 4 | 2.0 |
Tumor Cells, Cultured | 23 | 0.0 |
Cell Cycle/genetics/physiology | 2 | 13.0 |
DNA/*metabolism | 3 | 0.0 |
DNA Damage | 47 | 5.0 |
*DNA Repair | 14 | 2.0 |
Models, Biological | 18 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
Protein p53/genetics/metabolism | 2 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 34 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 118 | 0.0 |
Blotting, Western | 18 | 0.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Prognosis | 8 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 3 | 0.0 |
Survival Analysis | 3 | 0.0 |
Cell Line, Tumor | 14 | 0.0 |
Heterozygote | 15 | 0.0 |
Radiation Tolerance/*genetics | 6 | 10.0 |
BRCA2 Protein/genetics/metabolism | 2 | 40.0 |
DNA Repair/genetics | 4 | 2.0 |
Genes, BRCA1 | 7 | 3.0 |
Genes, BRCA2 | 3 | 2.0 |
Genotype | 12 | 0.0 |
*Germ-Line Mutation | 3 | 0.0 |
Polymorphism, Genetic | 5 | 0.0 |
Survival Rate | 4 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Apoptosis/*genetics | 3 | 1.0 |
Case-Control Studies | 10 | 0.0 |
DNA, Neoplasm/analysis | 4 | 0.0 |
DNA-Binding Proteins/genetics | 5 | 0.0 |
Neoplasm Proteins/genetics | 2 | 0.0 |
*Saccharomyces cerevisiae Proteins | 7 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
CpG Islands | 2 | 0.0 |
*DNA Methylation | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 14 | 0.0 |
Microscopy, Fluorescence | 6 | 0.0 |
Up-Regulation | 5 | 0.0 |
DNA, Neoplasm/chemistry/genetics | 2 | 1.0 |
Mutation, Missense | 4 | 0.0 |
Polymorphism, Single-Stranded Conformational | 7 | 0.0 |
Disease Progression | 4 | 0.0 |
*Gene Silencing | 2 | 1.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Transcription, Genetic | 7 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Catalysis | 5 | 0.0 |
Cell Cycle | 24 | 2.0 |
DNA/chemistry | 3 | 1.0 |
Animals | 87 | 0.0 |
*Antigens, Nuclear | 2 | 1.0 |
CHO Cells | 2 | 0.0 |
*DNA Helicases | 2 | 0.0 |
DNA Repair/*genetics | 5 | 1.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Gene Expression | 7 | 0.0 |
Hamsters | 3 | 0.0 |
Mutation | 35 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 3 | 1.0 |
DNA Damage/genetics | 5 | 11.0 |
Gene Deletion | 9 | 0.0 |
In Situ Hybridization, Fluorescence | 6 | 0.0 |
Lymphoma/*genetics | 2 | 4.0 |
Mice | 49 | 0.0 |
Mice, Knockout | 19 | 0.0 |
Protein-Serine-Threonine Kinases/*deficiency/genetics | 2 | 33.0 |
Recombination, Genetic/*genetics | 2 | 2.0 |
Time Factors | 20 | 0.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 3 | 1.0 |
*Cell Cycle Proteins | 8 | 0.0 |
Serine/metabolism | 8 | 2.0 |
BRCA1 Protein/metabolism | 3 | 8.0 |
DNA Damage/*physiology | 4 | 8.0 |
Protein Binding | 11 | 0.0 |
Radiation, Ionizing | 17 | 11.0 |
S Phase | 4 | 1.0 |
Imidazoles/pharmacology | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*physiology | 3 | 2.0 |
Ataxia Telangiectasia/genetics/metabolism | 2 | 50.0 |
Enzyme Activation | 15 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 3 | 0.0 |
Kinetics | 6 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 3 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/*physiology | 7 | 20.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
Ataxia Telangiectasia/genetics | 17 | 36.0 |
Neoplasms/genetics | 3 | 2.0 |
Signal Transduction | 29 | 0.0 |
Telomerase/metabolism | 5 | 9.0 |
Caffeine/pharmacology | 10 | 12.0 |
Cell Cycle Proteins/genetics/physiology | 3 | 25.0 |
RNA, Small Interfering/genetics | 2 | 1.0 |
Cell Nucleus/genetics | 2 | 6.0 |
DNA/genetics | 2 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Alleles | 12 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
In Vitro | 4 | 0.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Phenotype | 20 | 0.0 |
Transfection | 21 | 0.0 |
Breast Neoplasms/*genetics | 14 | 1.0 |
Chromosome Mapping | 6 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 3 | 1.0 |
Loss of Heterozygosity/genetics | 4 | 3.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Amino Acid Motifs | 5 | 0.0 |
Base Sequence | 17 | 0.0 |
Cell Cycle Proteins/metabolism | 12 | 3.0 |
DNA Replication | 2 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 5 | 0.0 |
K562 Cells | 2 | 0.0 |
Nuclear Proteins/metabolism | 5 | 0.0 |
*Phosphoproteins | 5 | 4.0 |
Ataxia Telangiectasia/*drug therapy/genetics | 2 | 100.0 |
Cells, Cultured | 18 | 0.0 |
Protein-Serine-Threonine Kinases/genetics | 11 | 8.0 |
*Radiation Tolerance | 3 | 5.0 |
Atmospheric Pressure | 4 | 30.0 |
Heart Rate/physiology | 2 | 2.0 |
Pressoreceptors/physiology | 2 | 20.0 |
BRCA1 Protein/genetics/*metabolism | 3 | 7.0 |
Macromolecular Substances | 5 | 0.0 |
Ataxia Telangiectasia | 3 | 30.0 |
*Ultraviolet Rays | 2 | 0.0 |
Cell Cycle Proteins/*genetics | 3 | 1.0 |
Microsatellite Repeats/genetics | 2 | 0.0 |
*Protein-Serine-Threonine Kinases | 55 | 6.0 |
Ataxia Telangiectasia/*genetics/metabolism | 2 | 100.0 |
Brain/*metabolism | 2 | 0.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
Chromosome Aberrations | 5 | 0.0 |
Phosphodiesterase Inhibitors/pharmacology | 3 | 2.0 |
Histones/*metabolism | 3 | 2.0 |
Hydroxyurea/pharmacology | 3 | 5.0 |
Ultraviolet Rays | 15 | 2.0 |
Carcinoma, Ductal, Breast/genetics | 2 | 11.0 |
Gene Frequency | 5 | 0.0 |
Genes, p53 | 7 | 1.0 |
Polymerase Chain Reaction | 18 | 0.0 |
BRCA2 Protein/genetics | 3 | 8.0 |
Breast Neoplasms/genetics | 3 | 1.0 |
Genes, p53/genetics | 6 | 2.0 |
Breast/metabolism | 2 | 2.0 |
Genes, erbB-2/genetics | 2 | 7.0 |
*Genetic Predisposition to Disease | 4 | 0.0 |
Loss of Heterozygosity | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 8 | 0.0 |
Cohort Studies | 2 | 0.0 |
Pregnancy | 5 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Bleomycin/pharmacology | 2 | 7.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Genes, p53/*genetics | 3 | 0.0 |
Precipitin Tests | 7 | 0.0 |
Protein Structure, Tertiary | 10 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Amino Acid Sequence | 12 | 0.0 |
Cell Cycle/*physiology | 4 | 1.0 |
Cell Nucleus/metabolism | 7 | 0.0 |
Chromatin/metabolism | 3 | 1.0 |
*DNA Replication | 4 | 1.0 |
Immunoblotting | 6 | 0.0 |
Molecular Sequence Data | 20 | 0.0 |
Recombinant Proteins/genetics/metabolism | 4 | 0.0 |
Disease Susceptibility | 4 | 0.0 |
English Abstract | 12 | 0.0 |
Protein-Serine-Threonine Kinases/*genetics/metabolism | 4 | 6.0 |
Continental Population Groups/genetics | 2 | 2.0 |
Exons/genetics | 4 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Protein-Serine-Threonine Kinases/chemistry/*genetics | 2 | 18.0 |
Temperature | 3 | 0.0 |
1-Phosphatidylinositol 3-Kinase/genetics | 2 | 16.0 |
Disease Models, Animal | 7 | 0.0 |
Leukemia/*genetics | 2 | 1.0 |
Ataxia Telangiectasia/*genetics/*metabolism | 2 | 66.0 |
Homozygote | 4 | 0.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
Protein-Serine-Threonine Kinases/*biosynthesis | 2 | 6.0 |
*Atmospheric Pressure | 7 | 38.0 |
Diving/*physiology | 3 | 42.0 |
Binding Sites | 7 | 0.0 |
Protein Kinases/*chemistry | 2 | 20.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 5 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Phosphorylation/radiation effects | 3 | 10.0 |
Plasmids/metabolism | 4 | 0.0 |
*Radiation, Ionizing | 5 | 20.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
*Hyperbaric Oxygenation | 8 | 50.0 |
Brain/metabolism | 2 | 0.0 |
Cell Survival | 6 | 0.0 |
*Cell Death | 2 | 4.0 |
*Genome | 2 | 1.0 |
Protein Processing, Post-Translational | 4 | 0.0 |
Sequence Alignment | 4 | 0.0 |
T-Lymphocytes | 2 | 0.0 |
Telomere/genetics/*metabolism | 2 | 22.0 |
Cell Cycle Proteins/genetics/metabolism | 4 | 5.0 |
Fungal Proteins/genetics/*metabolism | 2 | 3.0 |
Genes, Reporter | 3 | 0.0 |
Genes, cdc/physiology | 2 | 12.0 |
Genetic Complementation Test | 6 | 1.0 |
Mutation/genetics | 2 | 0.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 2 | 1.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
Child | 16 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Oxidative Stress | 4 | 1.0 |
Reactive Oxygen Species/metabolism | 3 | 0.0 |
CDC2 Protein Kinase/metabolism | 2 | 1.0 |
Cyclin B/metabolism | 2 | 2.0 |
Cyclins/physiology | 2 | 5.0 |
*G2 Phase | 3 | 8.0 |
Protein p53/*physiology | 3 | 2.0 |
Proteins/physiology | 2 | 1.0 |
Signal Transduction/genetics | 2 | 0.0 |
Oxidation-Reduction | 4 | 0.0 |
Immunoenzyme Techniques | 5 | 0.0 |
*Oxidative Stress | 2 | 0.0 |
Apoptosis | 5 | 0.0 |
B-Lymphocytes/cytology | 2 | 2.0 |
Cell Differentiation | 5 | 0.0 |
Nuclear Proteins/genetics | 4 | 1.0 |
*Chromosomal Instability | 2 | 25.0 |
DNA Damage/physiology | 2 | 7.0 |
DNA-Binding Proteins/metabolism | 4 | 0.0 |
Telomere/*metabolism | 2 | 7.0 |
Ataxia Telangiectasia/*genetics/pathology | 3 | 50.0 |
Fibroblasts/metabolism | 5 | 0.0 |
BRCA2 Protein | 6 | 1.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Recombination, Genetic | 5 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Breast Neoplasms/epidemiology/*genetics | 4 | 3.0 |
Gene Frequency/genetics | 2 | 0.0 |
Genes, BRCA1/*genetics | 3 | 1.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Mutation/*genetics | 5 | 0.0 |
Neoplasm Proteins/*genetics | 5 | 0.0 |
Transcription Factors/*genetics | 4 | 0.0 |
Analysis of Variance | 5 | 0.0 |
Immunohistochemistry | 10 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Ataxia Telangiectasia/metabolism | 2 | 40.0 |
Phosphoproteins/metabolism | 3 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/metabolism/*physiology | 3 | 27.0 |
G1 Phase | 3 | 0.0 |
G2 Phase | 7 | 4.0 |
Gamma Rays | 11 | 4.0 |
Protein p53/*metabolism | 9 | 1.0 |
Chronic Disease | 3 | 0.0 |
Fibrinolysis/*drug effects | 2 | 3.0 |
Follow-Up Studies | 3 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 8 | 3.0 |
Rabbits | 2 | 0.0 |
*Signal Transduction | 4 | 0.0 |
Pedigree | 5 | 0.0 |
Point Mutation | 7 | 0.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Risk Factors | 10 | 0.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Phosphorylation/drug effects | 3 | 0.0 |
Protein Kinases/*metabolism | 4 | 1.0 |
BRCA1 Protein/*genetics | 2 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Histones/chemistry | 2 | 11.0 |
Protein-Serine-Threonine Kinases/metabolism/*physiology | 3 | 13.0 |
Models, Molecular | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Species Specificity | 4 | 0.0 |
Cell Cycle Proteins/metabolism/*physiology | 2 | 13.0 |
Nuclear Proteins/metabolism/*physiology | 3 | 9.0 |
Germ-Line Mutation/*genetics | 2 | 1.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Frameshift Mutation | 2 | 0.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
Caspases/metabolism | 3 | 0.0 |
Mitosis | 3 | 0.0 |
*Gene Deletion | 7 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*biosynthesis/genetics | 2 | 8.0 |
Cell Division | 3 | 0.0 |
Alternative Splicing/genetics | 2 | 1.0 |
Denmark/epidemiology | 3 | 5.0 |
Heterozygote Detection | 2 | 0.0 |
Norway/epidemiology | 2 | 7.0 |
*Protein Kinases | 2 | 3.0 |
Sequence Deletion | 4 | 0.0 |
Germ-Line Mutation | 5 | 1.0 |
DNA-Binding Proteins/analysis | 2 | 2.0 |
*Loss of Heterozygosity | 2 | 0.0 |
Microsatellite Repeats | 3 | 0.0 |
Genes, Recessive | 2 | 0.0 |
Child, Preschool | 10 | 0.0 |
Infant | 4 | 0.0 |
Infant, Newborn | 6 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Nuclear Proteins/*physiology | 2 | 1.0 |
Proteins/genetics/metabolism | 2 | 1.0 |
Protein-Serine-Threonine Kinases/*analysis/genetics | 2 | 40.0 |
Enzyme Activation/radiation effects | 2 | 8.0 |
*Chromosome Deletion | 2 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 2 | 0.0 |
Genetic Markers | 5 | 0.0 |
Karyotyping | 3 | 0.0 |
Gene Therapy/*methods | 2 | 0.0 |
Tumor Cells, Cultured/radiation effects | 3 | 7.0 |
*Chromosome Breakage | 2 | 5.0 |
*Nuclear Proteins | 9 | 0.0 |
Radiation Tolerance | 5 | 5.0 |
Ataxia Telangiectasia/enzymology/genetics | 2 | 66.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Acute Disease | 3 | 0.0 |
Chromosome Breakage | 3 | 3.0 |
Fanconi Anemia/*complications/genetics/therapy | 2 | 100.0 |
Gene Therapy | 2 | 0.0 |
Histocompatibility Testing | 2 | 0.0 |
Leukemia, Myeloid/*complications/genetics/therapy | 2 | 100.0 |
Stem Cell Transplantation | 2 | 4.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Down-Regulation | 2 | 0.0 |
Protein-Serine-Threonine Kinases/analysis | 3 | 16.0 |
*Ataxia Telangiectasia | 2 | 100.0 |
Cell Cycle Proteins/genetics/*metabolism | 4 | 2.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Microsatellite Repeats/*genetics | 3 | 1.0 |
Cloning, Molecular | 6 | 0.0 |
Nucleic Acid Conformation | 3 | 0.0 |
DNA-Binding Proteins/*metabolism | 5 | 0.0 |
Protein Transport | 2 | 0.0 |
Chromosomes, Human, Pair 11 | 5 | 1.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Cell Cycle/genetics | 2 | 1.0 |
Exons | 4 | 0.0 |
Introns | 2 | 0.0 |
Translocation, Genetic | 3 | 0.0 |
Fibroblasts/radiation effects | 2 | 7.0 |
Pilot Projects | 2 | 0.0 |
Cell Cycle/*genetics | 3 | 4.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Adolescent | 15 | 0.0 |
Age of Onset | 2 | 0.0 |
*Genes, BRCA1 | 3 | 0.0 |
Ataxia Telangiectasia/etiology/*genetics/metabolism | 2 | 100.0 |
Meiosis | 2 | 1.0 |
Proteins/*genetics/metabolism | 5 | 1.0 |
Mice, Inbred Strains | 3 | 0.0 |
Neurons/*metabolism | 3 | 1.0 |
Mice, Transgenic | 2 | 0.0 |
Neoplasms, Experimental/genetics | 2 | 15.0 |
Rats | 5 | 0.0 |
United States | 2 | 0.0 |
*Genes, Recessive | 2 | 1.0 |
Proteins/genetics/physiology | 2 | 3.0 |
DNA Topoisomerases, Type I/antagonists & inhibitors | 2 | 8.0 |
Proteins/*physiology | 3 | 1.0 |
Camptothecin/pharmacology | 2 | 4.0 |
Cell Cycle/drug effects | 3 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Proteins/*genetics | 15 | 0.0 |
*Cell Cycle | 5 | 2.0 |
X-Rays | 2 | 1.0 |
Fibroblasts/metabolism/radiation effects | 3 | 15.0 |
Jurkat Cells | 2 | 0.0 |
Leucine Zippers | 5 | 3.0 |
Proteins/*metabolism | 2 | 0.0 |
Apoptosis/physiology | 2 | 0.0 |
DNA Repair/*physiology | 2 | 1.0 |
*Genes, Tumor Suppressor | 7 | 0.0 |
Proteins/genetics | 5 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
DNA Damage/*drug effects | 2 | 4.0 |
Signal Transduction/*physiology | 4 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Breast Neoplasms/*genetics/pathology | 2 | 0.0 |
Proteins/*genetics/*physiology | 2 | 11.0 |
Signal Transduction/physiology | 2 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
*Chromosomes, Human, Pair 11 | 3 | 0.0 |
Cell Aging/*physiology | 2 | 3.0 |
Protein-Serine-Threonine Kinases/physiology | 2 | 2.0 |
Antithrombin III/analysis | 3 | 1.0 |
Biological Markers/blood | 3 | 0.0 |
Plasminogen Activator Inhibitor 1/blood | 2 | 1.0 |
Bradycardia/*physiopathology | 2 | 50.0 |
Blotting, Northern | 4 | 0.0 |
Protein p53/*analysis/genetics | 2 | 9.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Genes, Structural/*genetics | 2 | 0.0 |
Apoptosis/genetics | 2 | 0.0 |
Phosphoserine/metabolism | 2 | 2.0 |
Proteins/genetics/*metabolism | 3 | 0.0 |
Zinostatin/pharmacology | 2 | 50.0 |
G1 Phase/genetics | 2 | 6.0 |
G2 Phase/genetics | 2 | 20.0 |
Protein p53/genetics/*metabolism | 2 | 1.0 |
Signal Transduction/*genetics | 2 | 1.0 |
Mice, Inbred C57BL | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Open Reading Frames | 3 | 0.0 |
*Point Mutation | 4 | 0.0 |
Circadian Rhythm | 2 | 0.0 |
*Diving | 3 | 60.0 |
Heart Rate | 2 | 0.0 |
Proteins/genetics/*physiology | 2 | 1.0 |
Antibiotics, Antineoplastic/pharmacology | 4 | 4.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
*Genes, p53 | 5 | 1.0 |
Great Britain | 2 | 0.0 |
Haplotypes | 6 | 0.0 |
Proteins/chemistry/*genetics | 2 | 1.0 |
Leukemia, Prolymphocytic/*genetics | 2 | 14.0 |
Fibroblasts/cytology/physiology | 2 | 2.0 |
Apoptosis/*genetics/radiation effects | 2 | 25.0 |
Radiotherapy Dosage | 2 | 1.0 |
Atmosphere Exposure Chambers | 2 | 66.0 |
Oxygen/*administration & dosage | 2 | 33.0 |
Partial Pressure | 4 | 8.0 |
Prospective Studies | 3 | 0.0 |
*Apoptosis | 4 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Blood Pressure | 2 | 0.0 |
Carbon Dioxide/blood | 2 | 5.0 |
Hematocrit | 2 | 0.0 |
Pressure | 7 | 5.0 |
Respiration | 2 | 3.0 |
Immunohistochemistry/methods | 3 | 0.0 |
1-Phosphatidylinositol 3-Kinase | 6 | 4.0 |
DNA Damage/*genetics | 5 | 8.0 |
*Chromosome Aberrations | 2 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Phosphotransferases (Alcohol Group Acceptor)/genetics | 3 | 21.0 |
Molecular Weight | 2 | 0.0 |
Hyperbaric Oxygenation/*adverse effects | 4 | 66.0 |
T-Lymphocytes/cytology/immunology | 2 | 2.0 |
*Chromosome Mapping | 2 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Cell Cycle Proteins/chemistry/*metabolism | 2 | 7.0 |
Osmolar Concentration | 2 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
*Telomere | 2 | 7.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
DNA, Viral/biosynthesis | 2 | 3.0 |
*Cardiopulmonary Bypass | 2 | 2.0 |
Double-Blind Method | 3 | 0.0 |
Fibrin Fibrinogen Degradation Products/analysis | 2 | 1.0 |
Thrombosis/etiology | 2 | 3.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Hemostasis/*physiology | 2 | 3.0 |
Platelet Count | 2 | 0.0 |
Genes, cdc | 3 | 6.0 |
Pregnancy Trimester, Third/blood | 2 | 28.0 |
Heart Rate/*physiology | 2 | 6.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Infrared Rays | 2 | 22.0 |
MAP Kinase Signaling System/drug effects/physiology | 2 | 6.0 |
Lymphoma, B-Cell/*genetics | 2 | 2.0 |
*Gene Expression Regulation | 2 | 0.0 |
Reference Values | 3 | 0.0 |
RNA Splicing/genetics | 2 | 1.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
U937 Cells | 2 | 0.0 |
DNA/chemistry/*metabolism | 2 | 3.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Heterozygote Detection/methods | 2 | 8.0 |
*Xenopus Proteins | 2 | 0.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Threonine/chemistry | 2 | 2.0 |
DNA/genetics/metabolism/*radiation effects | 2 | 100.0 |
